FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
National Taiwan University Hospital
Taipéi, TaiwánPublicaciones en colaboración con investigadores/as de National Taiwan University Hospital (5)
2024
-
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993
2023
-
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
JAMA network open, Vol. 6, Núm. 11, pp. e2342107
2022
-
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer
Future Oncology, Vol. 18, Núm. 34, pp. 3801-3813
2016
2015
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
New England Journal of Medicine, Vol. 373, Núm. 3, pp. 232-242